​​​​Luxena Pharmaceuticals, Inc. © ALL RIGHTS RESERVED

​​​​​Investors

Luxena Pharmaceuticals was founded by experienced drug developers with consistent regulatory approvals across multiple therapeutic areas.  Luxena develops products of low regulatory risks and high market potentials. Current pipeline includes re-formulated anti-emetics indicated for nausea and vomiting induced by chemotherapy, radiotherapy or surgery.  The company is currently financed by private funds.

Luxena Pharmaceuticals' success is warranted by a synergistic integration of the following ingredients:

Solid science

Growing product pipeline
Strong IP portfolio with multiple patents secured currently
Diversified partnerships for balanced business development
Understanding of patient needs and regulatory guidelines
Experienced team of management and advisory with proven track-record of drug development successes 
​

For more information on investment opportunities, please contact:

CEO and President

Luxena Pharmaceuticals, Inc.
info@luxenapharma.com